

## HEALTHCARE PROVIDER (HCP) INSTRUCTIONS:

- 1. Have your patient (or patient's representative) read page 3 (section 8): PATIENT AUTHORIZATION. Request that the patient (or patient's representative) sign the top section** to allow Acthar Patient Support to provide a complete level of support during the approval process. **If the patient (or patient's representative) would like to receive support, please have them sign the second section** to enroll in support and educational programs to receive additional information about their condition and treatment.
- 2. Complete pages 1 and 2 of the Acthar Referral Form.** Check the Acthar Injection Training Services box at the bottom of page 1 to request no-cost injection training for your patient.
- 3. Fax the completed Acthar Referral Form along with copies of the patient's pharmacy benefit card(s) (both front and back) to 1-877-937-2284.**
- Acthar Patient Support will process the Acthar Referral Form and contact both you and your patient (or patient's representative).
- Prior authorization assistance will only be provided for indicated disease states. Medicare, Medicaid and other federal or state program healthcare patients may be ineligible for certain other aspects of Acthar assistance programs.

## HCP SIGNATURE ON PAGE 1 AUTHORIZES PRESCRIPTION, CONSENT, AND STATEMENT OF MEDICAL NECESSITY

**By signing page 1**, I certify that Acthar<sup>®</sup> Gel is medically necessary for this patient and that I have reviewed this therapy with the patient and will be monitoring the patient's treatment. I verify that the patient and healthcare provider information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge. I understand that I must comply with my practicing state's specific prescription requirements, such as e-prescribing, using a state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to me by the dispensing pharmacy.

I authorize United BioSource LLC ("UBC"), the current operator of Acthar Patient Support, and other designated operators of the Program to perform a preliminary assessment of benefit verification for this patient and furnish information requested by the patient's insurer that is available on this form. I understand that insurance verification is ultimately the responsibility of the provider and that third-party reimbursement is affected by a variety of factors. While UBC tries to provide accurate information, they and Mallinckrodt make no representations or warranties as to the accuracy of the information provided.

I understand that representatives from the Program or UBC may contact me or my patient for additional information relating to this prescription. I acknowledge and agree that the designated Specialty Pharmacy will receive this prescription via a designated third party, the Program, and that no additional confirmation of receipt of prescription is required by the designated Specialty Pharmacy.

## PATIENT INSTRUCTIONS:

Your healthcare provider will submit the completed Acthar Referral Form to Acthar Patient Support. After we receive the form, we will call you so we can help you get your medicine. Please be on the lookout and answer calls from 1-800, 1-888, or blocked numbers. If you have any questions, please call **1-888-435-2284** Monday through Friday from 8 AM to 9 PM ET or Saturday from 9 AM to 2 PM ET.



PHARMACY NAME: \_\_\_\_\_

**1. PATIENT INFORMATION** Patient has been notified of referral  YES  NO

PATIENT FIRST NAME	PATIENT MIDDLE INITIAL	PATIENT LAST NAME	DATE OF BIRTH	GENDER
HOME ADDRESS	CITY		STATE	ZIP
SHIPPING ADDRESS (IF NOT HOME ADDRESS)	CARE OF (IF NOT ADDRESSED TO PATIENT)	CITY	STATE	ZIP
HOME PHONE	MOBILE	<input type="checkbox"/> OK TO TEXT	BEST TIME TO CALL	
EMAIL ADDRESS	PREFERRED LANGUAGE IF NOT ENGLISH			
ALTERNATIVE CONTACT NAME	RELATIONSHIP TO PATIENT		TELEPHONE	

**2. INSURANCE INFORMATION (PLEASE INCLUDE COPIES OF CARDS)**

PHARMACY BENEFITS	SUBSCRIBER ID #	GROUP #	TEL #
PRIMARY MEDICAL INSURANCE	SUBSCRIBER ID #	GROUP #	TEL #

**3. HEALTHCARE PROVIDER (HCP) INFORMATION**

HCP FIRST NAME	HCP MIDDLE INITIAL	HCP LAST NAME	NPI #	GROUP NPI # (IF APPLICABLE)	STATE LICENSE #
SPECIALTY: <input type="checkbox"/> NEUROLOGY <input type="checkbox"/> OTHER (PLEASE INDICATE) _____					
FACILITY NAME	TELEPHONE	FAX			
ADDRESS	CITY	STATE	ZIP		
OFFICE CONTACT NAME	CONTACT TELEPHONE	MOBILE NUMBER	EMAIL ADDRESS		
PREFERRED METHOD OF COMMUNICATION: <input type="checkbox"/> OFFICE PHONE <input type="checkbox"/> MOBILE PHONE <input type="checkbox"/> FAX <input type="checkbox"/> EMAIL <input type="checkbox"/> TEXT <input type="checkbox"/> NO PREFERENCE <input type="checkbox"/> PREFERRED CONTACT TIME: _____					

**4. PRESCRIPTION: ACTHAR<sup>®</sup> GEL** NDC# 63004-8710-1 5 mL multidose vial containing 80 USP units per mL

**4A. PLEASE SELECT FDA-APPROVED RECOMMENDED DOSE OR OTHER DOSE**

FDA-APPROVED RECOMMENDED DOSE  
75 UNITS/M2 (IM) TWICE DAILY FOR 2 WEEKS

OTHER DOSE: \_\_\_\_\_ UNITS  
SCHEDULE/FREQUENCY: \_\_\_\_\_  
HEIGHT: \_\_\_\_\_ in \_\_\_\_\_ cm WEIGHT: \_\_\_\_\_ kg \_\_\_\_\_ lb

QUANTITY OF 5 mL MULTIDOSE VIALS: \_\_\_\_\_ REFILLS: \_\_\_\_\_

**4B. TAPER INSTRUCTIONS**

ADDITIONAL SPECIAL INSTRUCTIONS, TITRATION OR TAPER DOSE, IF APPLICABLE:

SEE ATTACHED TAPER SCHEDULE FOR ADDITIONAL TAPER INSTRUCTIONS

**4C. ICD-10 CODE:** \_\_\_\_\_  
**PRIMARY DIAGNOSIS CODES ON PAGE 2, SECTION 6**

IS Dosing Calculator is available at:  
[www.actharishcp.com/acthar-dosing-calculator](http://www.actharishcp.com/acthar-dosing-calculator),  
or the iTunes or Google Play App stores

**4D. IDENTIFYING SUPPLIES IS MANDATORY FOR A COMPLETE PRESCRIPTION**

**SYRINGE SIZE:**  
 1 mL  Other: \_\_\_\_\_  
 1 box of 100  Other: \_\_\_\_\_

**NEEDLE SIZE FOR DRAWING:**  20 G needle, 1"  Other: \_\_\_\_\_  
 1 box of 100  Other: \_\_\_\_\_

**NEEDLE SIZE FOR INTRAMUSCULAR INJECTING:**  23 G needle, 5/8"  23 G needle, 3/4"  23 G needle, 1"  
 1 box of 100  Other: \_\_\_\_\_

SUPPLY REFILLS: \_\_\_\_\_ SHARPS CONTAINER: \_\_\_\_\_

**5. STARTER PROGRAM**

Starter product is optional and available at no cost to eligible commercially insured patients (see Starter Program Terms & Conditions on page 3). I authorize Mallinckrodt to forward this prescription to the Acthar Commercial Starter Program-designated pharmacy in order to dispense Acthar directly to the above-named patient. The Acthar Commercial Starter Program dispensing pharmacy will contact the patient for each vial shipment. Noncompliance with state-specific requirements could result in outreach to me by the dispensing pharmacy.

**5A. PLEASE SELECT FDA-APPROVED RECOMMENDED DOSE OR OTHER DOSE**

FDA-APPROVED RECOMMENDED DOSE  
75 UNITS/M2 (IM) TWICE DAILY FOR 2 WEEKS

OTHER DOSE: \_\_\_\_\_ UNITS  
SCHEDULE/FREQUENCY: \_\_\_\_\_  
HEIGHT: \_\_\_\_\_ in \_\_\_\_\_ cm WEIGHT: \_\_\_\_\_ kg \_\_\_\_\_ lb

QUANTITY OF 5 mL MULTIDOSE VIALS: 1 REFILLS: 3

**5B. TAPER INSTRUCTIONS**

ADDITIONAL SPECIAL INSTRUCTIONS, TITRATION OR TAPER DOSE, IF APPLICABLE:

SEE ATTACHED TAPER SCHEDULE FOR ADDITIONAL TAPER INSTRUCTIONS

SAME PATIENT SHIPPING ADDRESS AS ABOVE  OTHER SHIPPING ADDRESS: \_\_\_\_\_

**5C. ICD-10 CODE:** \_\_\_\_\_  
**PRIMARY DIAGNOSIS CODES ON PAGE 2, SECTION 6**

IS Dosing Calculator is available at:  
[www.actharishcp.com/acthar-dosing-calculator](http://www.actharishcp.com/acthar-dosing-calculator),  
or the iTunes or Google Play App stores

**5D. IDENTIFYING SUPPLIES IS MANDATORY FOR A COMPLETE PRESCRIPTION**

**SYRINGE SIZE:**  
 1 mL  Other: \_\_\_\_\_  
 1 box of 100  Other: \_\_\_\_\_

**NEEDLE SIZE FOR DRAWING:**  20 G needle, 1"  Other: \_\_\_\_\_  
 1 box of 100  Other: \_\_\_\_\_

**NEEDLE SIZE FOR INTRAMUSCULAR INJECTING:**  23 G needle, 5/8"  23 G needle, 3/4"  23 G needle, 1"  
 1 box of 100  Other: \_\_\_\_\_

SUPPLY REFILLS: \_\_\_\_\_ SHARPS CONTAINER: \_\_\_\_\_

**ACTHAR INJECTION TRAINING SERVICES**

By checking here, I request that company-funded Acthar Injection Training Services be arranged for my patient. I understand that Acthar Injection Training Services are available for multiple visits but are NOT a home health nursing service. Patients can contact their Nurse Navigator at any time about injection training.

HCP Prescriber Signature - Please sign only ONE LINE below (by signing below you are agreeing to the HCP Consent section on the cover page of this document)

DISPENSE AS WRITTEN \_\_\_\_\_ DATE \_\_\_\_\_ **OR**  SUBSTITUTIONS ALLOWED \_\_\_\_\_ DATE \_\_\_\_\_

Please print out and provide a wet signature as not all Specialty Pharmacies accept digital signatures. Prescriber signature required for consent and to validate prescriptions. Prescriber attests that this is her/his signature. NO STAMPS. By signing, prescriber certifies that the above is medically necessary.

**6. DIAGNOSIS AND MEDICAL INFORMATION**

**DIAGNOSIS CODES**

Please check all diagnosis codes that correspond with patient's diagnosis. Below is a list of common ICD-10 codes. You may also write in the patient's diagnosis in the "OTHER" section.

**INFANTILE SPASMS (IS)**

**Infantile spasms (IS)**

Has diagnosis been confirmed by EEG?

YES  NO

Requested drug delivery date: \_\_\_\_\_

- EPILEPTIC SPASMS, NOT INTRACTABLE, WITH STATUS EPILEPTICUS  
**G40.821**
- EPILEPTIC SPASMS, NOT INTRACTABLE, WITHOUT STATUS EPILEPTICUS  
**G40.822**
- EPILEPTIC SPASMS, INTRACTABLE, WITH STATUS EPILEPTICUS  
**G40.823**
- EPILEPTIC SPASMS, INTRACTABLE, WITHOUT STATUS EPILEPTICUS  
**G40.824**
- Other: \_\_\_\_\_

**7. RELEVANT TREATMENT HISTORY AND CONCURRENT MEDICATIONS (INCLUDING RECENT STEROID HISTORY, IF APPLICABLE)**

Therapy Name	Dose	Start Date	Stop Date (if applicable)	Explain Outcome With Detail (eg, type of outcome)

**OTHER RELEVANT CLINICAL INFORMATION (INCLUDING ALLERGIES)**

**HCP SIGNATURE: REQUIRED FOR DOCUMENTATION**

I verify that the patient and healthcare provider information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge. I certify that my patient has agreed in writing to be contacted by Program administrators or UBC and be furnished with Program or other information or materials.

NAME \_\_\_\_\_ SIGNATURE \_\_\_\_\_ DATE \_\_\_\_\_

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

**8. PATIENT AUTHORIZATION(S)**

**Patient Consent to allow Acthar Patient Support Team to work together with your insurance provider, pharmacy, advocacy organization and others to provide support on your behalf.**

By signing this authorization, I authorize my physician(s), my health insurance company and my pharmacy providers (collectively, "Designated Parties") to disclose to Mallinckrodt ARD Inc. ("Mallinckrodt"), the distributor of Acthar, and its agents, authorized designees and contractors, including Mallinckrodt reimbursement support personnel and United BioSource LLC ("UBC") or any other operator of the Acthar Hub on behalf of Mallinckrodt (collectively, "Manufacturer Parties"), health information relating to my medical condition, treatment and insurance coverage (my "Health Information") in order for them to (1) provide certain services to me, including reimbursement and coverage support, patient assistance and access programs, medication shipment tracking, and home injection training, (2) provide me with support services and information associated with my Acthar therapy, (3) serve internal business purposes, such as marketing research, internal financial reporting and operational purposes, and (4) carry out the Manufacturer Parties' respective legal responsibilities.

Once my Health Information has been disclosed to Manufacturer Parties, I understand that it may be redisclosed by them and no longer protected by federal and state privacy laws. However, Manufacturer Parties agree to protect my Health Information by using and disclosing it only for the purposes detailed in this authorization or as permitted or required by law.

I understand that I may refuse to sign this authorization and that my physician and pharmacy will not condition my treatment on my agreement to sign this authorization form, and my health plan or health insurance company will not condition payment for my treatment, insurance enrollment or eligibility for insurance benefits on my agreement to sign this authorization form. I understand that my pharmacies and other Designated Parties may receive payment in connection with the disclosure of my Health Information as provided in this authorization. I understand that I am entitled to receive a copy of this authorization after I sign it.

I may revoke (withdraw) this authorization at any time by mailing a letter to the Acthar Hub, 255 Technology Park, Lake Mary, FL 32746. Revoking this authorization will end further disclosure of my Health Information to Manufacturer Parties by my pharmacy, physicians, and health insurance company when they receive a copy of the revocation, but it will not apply to information they have already disclosed to Manufacturer Parties based on this authorization. I also know I may cancel my enrollment in a patient support program at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling the Acthar Hub at 1-888-435-2284. This authorization is in effect for 5 years unless a shorter period is provided for by state law or until the conclusion of any ongoing coverage support, whichever is longer, once I have signed it unless I cancel it before then.

THIS SECTION MUST BE COMPLETED IN ITS ENTIRETY, INCLUDING DATE

▶ \_\_\_\_\_  
PATIENT NAME OR LEGAL REPRESENTATIVE      PATIENT SIGNATURE      IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT      DATE

**Patient Consent to receive additional information from Mallinckrodt such as education on your disease and Acthar.**

I authorize Mallinckrodt and its partners to use, disclose, and/or transfer the personal information I supply (1) to contact me and provide me with informational and marketing materials and clinical trial opportunities related to my condition or treatment by any means of communication, including but not limited to text, email, mail, or telephone; (2) to help Mallinckrodt improve, develop, and evaluate products, services, materials, and programs related to my condition or treatment; (3) to enroll me in and provide me with Acthar-related programs and services that I may select or refuse at any time; (4) to disclose my enrollment and use of these services to my healthcare providers and insurers; and (5) to use my information that cannot identify me for scientific and market research. This authorization will remain in effect until I cancel it, which I may do at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling the Acthar Hub at 1-888-435-2284. I may request a copy of this signed authorization.

▶ \_\_\_\_\_  
PATIENT NAME OR LEGAL REPRESENTATIVE      PATIENT SIGNATURE      IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT      DATE

If patient is not present to sign the form, send them to  
**ActharConsent.com**  
and have them sign electronically.

**Starter Program Terms & Conditions:** This program is not valid for patients covered by Medicare, Medicare D, Medicare Advantage Plans, or Medicaid plans [including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange, TRICARE, Department of Defense (DOD), Veterans Affairs (VA), or any other state or federal medical or pharmacy benefit program]. For full terms and conditions, please see Acthar.com.

## INDICATIONS AND USAGE

- **Infantile spasms:** Acthar Gel (repository corticotropin injection) is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
- **Multiple Sclerosis:** Acthar Gel is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
- **Rheumatic Disorders:** As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis
- **Collagen Diseases:** During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
- **Dermatologic Diseases:** Severe erythema multiforme, Stevens-Johnson syndrome
- **Allergic States:** Serum sickness
- **Ophthalmic Diseases:** Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis; anterior segment inflammation
- **Respiratory Diseases:** Symptomatic sarcoidosis
- **Edematous State:** To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

## IMPORTANT SAFETY INFORMATION

### Contraindications

- Acthar should never be administered intravenously
- Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
- Acthar is contraindicated where congenital infections are suspected in infants
- Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

### Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
- There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
- Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

### Adverse Reactions

- Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
- Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

**Other adverse events reported are included in the full Prescribing Information.**

**Please see accompanying full Prescribing Information and Medication Guide.**